Pharmaceutical Intermediate Market projected to reach US$ 37,290.33 million by 2028 | Codexis, chiracon, Vertellus Holdings, Lianhe Chemical Technology,
The pharmaceutical intermediate market was valued at US$ 27,356.70 million in 2020 and is projected to reach US$ 37,290.33 million by 2028; it is expected to grow at a CAGR of 4.2% from 2021 to 2028.
The pharmaceutical intermediate market is segmented on the basis of type, application, distribution channel, and region. The market, based on region, is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the pharmaceutical intermediate market emphasizing on various parameters, such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the world. It also includes the impact of the COVID–19 pandemic on the market across all the regions. A recent survey by the World Health Organization (WHO) found that health services are among the most frequently disrupted. 7 in 10 countries around the worldwide are experiencing disruptions along with the United statesS, Canada and Mexico. However, as per the IRI data, demand for various dietary supplements rushed at the onset of the coronavirus COVID-19 pandemic in the U.S. at the unprecedented rates. The total supplement sales increased by 6% during the first week of March 2020. Also, due to social distancing practices consumers are experiencing changes to their daily routines of grooming and skin care. This has led to an increased demand for nutrition products that can be used at home. Also, the rising incidence number of COVID-19 patients has increased the demand for analgesics. This is likely to favor the growth of the pharmaceutical intermediates market.
Request for Free Sample PDF Copy at: https://www.theinsightpartners.com/sample/TIPRE00005559/
Pfizer Inc., .; Sanofi, ; BASF SE, ; Lianhe Chemical Technology Co., Ltd, ; Dishman Carbogen Amcis Ltd, ; Codexis, ; Midas Pharma GmbH, ; chiracon GmbH, ; Dextra Laboratories Limited, ; and Vertellus Holdings LLC are among the leading companies operating in the pharmaceutical intermediate market. The companies are adopting inorganic and organic growth strategies to expand their global footprints and product portfolio to meet the rising demands for the pharmaceutical intermediate. For instance, in January 2021, Pritzker Private Capital, a leader in family direct investing, acquired the Vertellus group of companies, a specialty chemicals manufacturer. Headquartered in Indianapolis, Ind., Vertellus is a leading provider of specialty chemicals for the healthcare, personal care, food & agriculture, coatings, and transportation markets.
In 2020, the GMP segment accounted for the global pharmaceutical intermediate market's a largerst market share of the global pharmaceutical intermediate market. The market growth for this segment can be attributed to increase in adoption of good manufacturing practices (GMP) by pharmaceutical companies. Good Manufacturing Practice (GMP) are regulations by the US Food and Drug Administration that ensure that pharmaceutical products are consistently produced as per the quality standards. These regulations are designed to reduce the risks involved in the production of pharmaceuticals that cannot be eliminated through testing the finished product.
The surging prevalence of infectious diseases, especially in Southeast Asia, is also likely to propel the demand for APIs in the coming years, eventually driving the growth of the pharmaceutical intermediate market. For instance, as per the Revised National Tuberculosis Control Programme Report, around 4.4 lakh patients died due to tuberculosis in India in 2018, that is 29% of the total 1.5 million deaths caused by the disease across the world. Thus, such high prevalence of chronic diseases and infectious diseases is bolstering the demand for drugs, eventually highlighting the need of pharmaceutical intermediates.
Pharmaceutical intermediates are the building blocks of active pharmaceutical ingredients (APIs). These are raw materials that undergo molecular change or processing during bulk drug production. Thus, the requirement of pharmaceutical intermediates increases with the rise in demand for drugs to treat chronic diseases. As per the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the US suffer from at least one chronic disease such as cancer, heart disease, lung disease, stroke, neurological disease, diabetes, and kidney diseases. Moreover, 4 in 10 adults in the country have two or more chronic diseases. Additionally, according to the press release by the European Chronic Disease Alliance (ECDA), in 2014, 9 out of 10 people in Europe die due to chronic diseases. Thus, 70–80% of the total healthcare costs are spent on the management of chronic diseases.
- Non GMP
- Antipyretic Analgesics
By Distribution Channel
- Direct Sales
Place an Order Copy of This Report at: https://www.theinsightpartners.com/buy/TIPRE00005559/